Peptides for Menopause in South Africa

Menopause is one of the most predictable events in human biology and one of the least well-supported. South African research going back two decades has described women who felt the physical and psychological changes simply had to be endured, and who had not been given much information either way.

That is changing, slowly. But the conversation still tends to collapse into a single binary — hormone therapy or nothing — which leaves a lot of women without a useful answer.

This article covers what actually changes at menopause, where menopausal hormone therapy sits in South African clinical guidance, and where peptides are being used alongside or instead of it. It is not a substitute for a conversation with a doctor who knows your history, and it does not pretend peptides replace hormone therapy.

What Actually Changes

The median age of menopause is around 51, with a normal range from roughly 45 to 55. The transition — perimenopause — commonly begins several years before the final period and is when symptoms are often at their most disruptive, precisely because hormone levels are fluctuating rather than simply low.

The changes worth understanding:

Vasomotor symptoms. Hot flushes and night sweats are the signature symptom. The important and under-communicated finding from the SWAN cohort is duration: frequent vasomotor symptoms lasted more than seven years for over half the women studied, and persisted a median of four and a half years after the final period. This is not a few difficult months.

Sleep. Sleep disturbance rises sharply across the transition, and it is not only a consequence of night sweats. Around a quarter of women in the menopausal transition meet criteria for insomnia. Because sleep governs so much else — glucose handling, appetite regulation, mood, recovery, cognition — this is often the symptom whose knock-on effects are most underestimated.

Skin and collagen. Oestrogen has a direct effect on dermal collagen. The classic work here found a measurable decline in skin collagen content after menopause, and that it tracked years since menopause rather than chronological age. This is why skin change at menopause often feels abrupt rather than gradual.

Body composition and metabolism. Fat distribution shifts toward the abdomen, lean mass becomes harder to hold, and insulin sensitivity commonly worsens. The same eating and training that worked at 40 stops working at 50, which is genuinely a physiological change rather than a failure of effort.

Mood, drive and libido. All are commonly affected, through a combination of direct hormonal effects, disrupted sleep and the cumulative weight of the other symptoms.

Where Hormone Therapy Sits

It would be dishonest to write about menopause and skip past hormone therapy, so let us be clear about it.

Menopausal hormone therapy remains the most effective treatment available for vasomotor symptoms and for the genitourinary syndrome of menopause, and it prevents bone loss and fracture. That is the position of the North American Menopause Society in its 2022 statement, and the South African Menopause Society has published its own consensus position statement for local practitioners.

The current framing, after two decades of reassessment following the Women's Health Initiative, is that for most healthy symptomatic women under 60 and within ten years of menopause onset, the benefits outweigh the risks. It must be individualised to symptoms, history and preference, and reviewed periodically.

If your symptoms are significant and you have not had a proper conversation about hormone therapy with a practitioner who is current on the evidence, that conversation is the highest-value thing you can do. Peptides are not a replacement for it.

One local practicality worth knowing: the range of registered options in South Africa is narrower than in some other markets, which is part of why compounded preparations have a following here. The South African Menopause Society has published specific guidance on compounded bioidentical hormone therapy, and it is worth reading before going that route.

Where Peptides Are Being Used

With that framing in place, here is where peptides come into the picture for women navigating this transition. These are research compounds, used for research purposes, and the framing below is about mechanism and what people commonly use them for — not a claim that they treat menopause.

Sleep and nervous system. DSIP is the compound most directly associated with sleep architecture, and Selank is used where the barrier is a wired, anxious quality to the evening rather than sleep onset alone. Given how central sleep disruption is to the rest of the picture, this is often where people start.

Skin and collagen. GHK-Cu is the most researched peptide for skin regeneration. It stimulates collagen synthesis in fibroblast culture at very low concentrations, and gene expression work has documented broad effects on repair and remodelling pathways. Given that the collagen decline at menopause is well documented, the mechanistic fit here is unusually direct. It is used both topically and subcutaneously.

Cellular and energy support. NAD+ declines with age and is required for sirtuin and DNA-repair enzyme activity. Epithalon is used in defined short courses in longevity-focused protocols. Neither is menopause-specific; both address a background that menopause sits on top of.

Drive and libido. PT-141 works through melanocortin receptors in the brain rather than on blood flow, which is why it is relevant to desire specifically. Its pharmaceutical form, bremelanotide, went through phase 3 trials and was approved in the United States for hypoactive sexual desire disorder in premenopausal women. That approval is specifically for premenopausal women, which is an important limitation to state plainly rather than gloss over.

Body composition. Where central weight gain is the dominant concern, the GLP-1 class is the evidence-backed option, and it is a conversation to have with a doctor.

STRIATA's Menopause Reset protocol groups several of these into four stacks aimed at the symptom clusters above — sleep, renewal, skin and vitality — for people who prefer a structured approach to assembling compounds individually.

A Sensible Order of Operations

If you are in this transition and trying to work out where to start:

1. 1.[Get bloods done](/guides/peptide-bloodwork-guide). Thyroid function, ferritin, vitamin D, HbA1c, fasting insulin and lipids. Thyroid disease and iron deficiency both mimic menopause symptoms and both are common in South African women. Treating the wrong thing wastes years.
2. 2.Have the hormone therapy conversation properly, with someone current on the evidence, before deciding it is not for you.
3. 3.Fix sleep first among the remaining symptoms. Almost everything else improves marginally when sleep does, and almost nothing improves while it is broken.
4. 4.Then address the specific cluster that bothers you most, rather than everything simultaneously. You cannot tell what worked if you changed six variables.
5. 5.Give it time and retest. Skin and body composition changes are measured over months, not weeks.

The Bottom Line

Menopause is a long transition with real physiological consequences, and the evidence base for managing it is better than the support most South African women actually receive.

Hormone therapy is the most effective option for the core symptoms and deserves a proper conversation. Peptides sit alongside it, addressing sleep, skin, cellular energy and drive through different mechanisms. Neither replaces bloodwork, and neither replaces a practitioner who knows your history.

Sources

The research, regulatory documents and clinical guidelines behind the claims in this article:

• Greendale GA, Lee NP, Arriola ER. The menopause. The Lancet, 1999.
• Davis SR, Lambrinoudaki I, et al. Menopause. Nature Reviews Disease Primers, 2015.
• Avis NE, Crawford SL, et al. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Internal Medicine, 2015.
• Baker FC, de Zambotti M, et al. Sleep problems during the menopausal transition: prevalence, impact, and management challenges. Nature and Science of Sleep, 2018.
• Brincat M, Moniz CF, et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. British Journal of Obstetrics and Gynaecology, 1987.
• The North American Menopause Society Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 2022.
• Guidozzi F, Alperstein A, et al. South African Menopause Society revised consensus position statement on menopausal hormone therapy. South African Medical Journal, 2014.
• Manson JE, Chlebowski RT, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA, 2013.
• Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988.
• Pickart L, Vasquez-Soltero JM, Margolina A. GHK and DNA: resetting the human genome to health. BioMed Research International, 2014.
• Kingsberg SA, Clayton AH, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials (RECONNECT). Obstetrics and Gynecology, 2019.
• Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine, 2003.
• Covarrubias AJ, Perrone R, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology, 2021.

Disclaimer: The information in this article is for educational purposes only and is not medical advice. It does not diagnose or prescribe. STRIATA peptides are research compounds, are not approved medicines and are not registered treatments for menopause. Menopausal hormone therapy decisions should be made with a qualified healthcare practitioner.